Nuntius Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 5

Nuntius Therapeutics General Information

Description

Developer of genetic medicines designed to cure patients with life-threatening diseases. The company develops mRNA therapies and gene editing therapies by leveraging proprietary delivery technology, machine learning, and nucleic acid engineering, enabling healthcare professionals to treat incurable diseases and improve patient outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 23 The Cobalt Building, Lower Pemberton
  • Kent
  • Ashford TN25 4BF
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Unit 23 The Cobalt Building, Lower Pemberton
  • Kent
  • Ashford TN25 4BF
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nuntius Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 01-Apr-2021 Completed Generating Revenue
1. Accelerator/Incubator 23-Mar-2021 Completed Generating Revenue
To view Nuntius Therapeutics’s complete valuation and funding history, request access »

Nuntius Therapeutics Patents

Nuntius Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202216550-D0 Extrahepatic delivery Inactive 07-Nov-2022
GB-202216131-D0 Extrahepatic delivery Inactive 31-Oct-2022
GB-202212998-D0 Molecular fingerprinting Inactive 06-Sep-2022
EP-4581633-A1 Methods for characterisation of nanocarriers Pending 02-Sep-2022
GB-202212806-D0 Methods for characterisation of nanocarriers Inactive 02-Sep-2022 G16C60/00
To view Nuntius Therapeutics’s complete patent history, request access »

Nuntius Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nuntius Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Asymmetry Ventures Venture Capital Minority
Backed Venture Capital Minority
FoundersX Ventures Venture Capital Minority
Uncommon Denominator Venture Capital Minority
Y Combinator Accelerator/Incubator Minority
To view Nuntius Therapeutics’s complete investors history, request access »

Nuntius Therapeutics FAQs

  • When was Nuntius Therapeutics founded?

    Nuntius Therapeutics was founded in 2021.

  • Where is Nuntius Therapeutics headquartered?

    Nuntius Therapeutics is headquartered in Ashford, United Kingdom.

  • What is the size of Nuntius Therapeutics?

    Nuntius Therapeutics has 8 total employees.

  • What industry is Nuntius Therapeutics in?

    Nuntius Therapeutics’s primary industry is Drug Discovery.

  • Is Nuntius Therapeutics a private or public company?

    Nuntius Therapeutics is a Private company.

  • What is Nuntius Therapeutics’s current revenue?

    The current revenue for Nuntius Therapeutics is .

  • How much funding has Nuntius Therapeutics raised over time?

    Nuntius Therapeutics has raised $125K.

  • Who are Nuntius Therapeutics’s investors?

    Asymmetry Ventures, Backed, FoundersX Ventures, Uncommon Denominator, and Y Combinator have invested in Nuntius Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process